MET and lung carcinoma: Likewise, in GSE253742, MET, ETS-1, and USP9X expression levels in lung cancer tissues after osimertinib treatment were elevated compared to untreated lung cancer tissues, supporting our research findings (Supplementary Fig. 4C).